The UK and US have forged a landmark commercial pact that will ensure no levies on UK medicine products entering the US market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to boost spending on drugs through the National Health Service (NHS). This commitment ensures that tariffs on these crucial exports will be held at zero for a timeframe of three years.
This agreement follows recent statements to significantly raise tariffs on patented drug imports, with potential rates floated as high as double the cost.
"This deal with the United Kingdom reinforces the global environment for cutting-edge drugs and introduces long-overdue balance to American-British pharmaceutical trade," a statement said.
Economic Significance
Medicines represent one of the Britain's most significant export categories to the US, which is clearly the largest buyer for leading companies like GSK and AstraZeneca.
Trade data show that in the one-year period prior to the third quarter, the UK exported medicines valued at over eleven billion pounds to the US. This figure accounted for a significant portion of all goods exports in that period.
"This deal protects jobs, boosts funding and facilitates the UK to become a global hub for life sciences," a minister remarked.
Detailed British Pledges
The deal entails several specific changes from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it deems new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to raise overall public funding on drugs from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The sum manufacturers must refund to the NHS to stay within budget will be restricted at fifteen percent. Last year, repayments exceeded twenty percent.
Industry Background
The deal follows a protracted dispute between the pharmaceutical industry and the ministers over medicine costs and approval rates.
The disagreement were intensified by claims that US patients were paying a premium for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar investments have been pledged toward projects in the United States.
One official acknowledged that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had declined as a percentage of its resources over the previous ten-year period.
